Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)

Ozsvari, B, Sotgia, F and Lisanti, MP

10.18632/aging.101384

<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Authors</strong></td>
<td>Ozsvai, B, Sotgia, F and Lisanti, MP</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Article</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td>This version is available at: <a href="http://usir.salford.ac.uk/id/eprint/46175/">http://usir.salford.ac.uk/id/eprint/46175/</a></td>
</tr>
<tr>
<td><strong>Published Date</strong></td>
<td>2018</td>
</tr>
</tbody>
</table>

USIR is a digital collection of the research output of the University of Salford. Where copyright permits, full text material held in the repository is made freely available online and can be read, downloaded and copied for non-commercial private study or research purposes. Please check the manuscript for any further copyright restrictions.

For more information, including our policy and submission procedure, please contact the Repository Team at: usir@salford.ac.uk.
Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)

Bela Oszvari¹², Federica Sotgia¹², Michael P. Lisanti¹²

¹Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester, United Kingdom
²The Paterson Institute, University of Manchester, Withington, United Kingdom

Correspondence to: Michael P. Lisanti, Federica Sotgia; email: michaelp.lisanti@gmail.com, fsotgia@gmail.com

Keywords: tri-phenyl-phosphonium (TPP); cancer stem cells (CSCs); cancer therapy; mitochondrial targeting signal

Received: November 25, 2017   Accepted: February 9, 2018   Published: February 19, 2018

ABSTRACT

Tri-phenyl-phosphonium (TPP) is a non-toxic chemical moiety that functionally behaves as a mitochondrial targeting signal (MTS) in living cells. Here, we explored the hypothesis that TPP-related compounds could be utilized to inhibit mitochondria in cancer stem cells (CSCs). We randomly selected 9 TPP-related compounds for screening, using an ATP depletion assay. Based on this approach, five compounds were identified as “positive hits”; two had no detectable effect on ATP production. Remarkably, this represents a >50% hit rate. We validated that the five positive hit compounds all inhibited oxygen consumption rates (OCR), using the Seahorse XFe96 metabolic flux analyzer. Interestingly, these TPP-related compounds were non-toxic and had little or no effect on ATP production in normal human fibroblasts, but selectively targeted adherent “bulk” cancer cells. Finally, these positive hit compounds also inhibited the propagation of CSCs in suspension, as measured functionally using the 3D mammosphere assay. Therefore, these TPP-related compounds successfully inhibited anchorage-independent growth, which is normally associated with a metastatic phenotype. Interestingly, the most effective molecule that we identified contained two TPP moieties (i.e., bis-TPP). More specifically, 2-butene-1,4-bis-TPP potently and selectively inhibited CSC propagation, with an IC-50 < 500 nM. Thus, we conclude that the use of bis-TPP, a “dimeric” mitochondrial targeting signal, may be a promising new approach for the chemical eradication of CSCs. Future studies on the efficacy of 2-butene-1,4-bis-TPP and its derivatives are warranted. In summary, we show that TPP-related compounds provide a novel chemical strategy for effectively killing both i) “bulk” cancer cells and ii) CSCs, while specifically minimizing or avoiding off-target side-effects in normal cells. These results provide the necessary evidence that “normal” mitochondria and “malignant” mitochondria are truly biochemically distinct, removing a significant barrier to therapeutically targeting cancer metabolism.

INTRODUCTION

Cancer stem cells (CSCs) are tumor-initiating cells (TICs) [1, 2] that appear to be the biological basis of treatment failure, due to tumor recurrence and distant metastasis [3-7], ultimately leading to poor clinical outcome in cancer patients. As a consequence, new therapies are urgently needed, to specifically target and eradicate CSCs [1-7]. Circulating tumor cells (CTCs) also directly share many key functional properties with CSCs [1-7].

Interestingly, recent studies indicate that one unique feature of CSCs is a characteristic increase in mitochondrial mass [8], which may reflect a more strict dependence on mitochondrial function or OXPHOS
Several independent lines of evidence support the idea that increased mitochondrial biogenesis or higher levels of mitochondrial protein translation may occur in CSCs [8-18]. For example, unbiased proteomics analysis directly shows that mitochondrial mass is elevated in CSCs [8].

Moreover, MitoTracker (a fluorescent mitochondrial dye) can be used successfully as a marker to identify and purify CSCs [9,10]. Specifically, the “Mito-high” cell population showed the greatest capacity for increased i) anchorage-independent growth and ii) tumor-initiating ability in vivo [10].

High telomerase activity also directly correlated with high mitochondrial mass and the ability of CSCs to undergo proliferative expansion [13]. Similarly, high mitochondrial mass in CSCs was also specifically associated with mitochondrial ROS production (hydrogen peroxide) [12] and could be targeted with either: i) inhibitors of mitochondrial anti-oxidants [19,20], ii) inhibitors of mitochondrial biogenesis (doxycycline) [11,13,14,18] or OXPHOS (atovaquone) [11,16,17], and even iii) inhibitors of cell proliferation (palbociclib, a CDK4/6 inhibitor) [13].

The above findings immediately suggest a new approach for the eradication of CSCs, via the development of novel mitochondrial inhibitors. Here, we provide a new strategy for the identification of novel non-toxic mitochondrial inhibitors, using TPP-based compounds, with proof-of-concept.

TPP serves as a chemical mitochondrial targeting signal [21]. Importantly, we directly showed that these TPP compounds are non-toxic in normal fibroblasts, but potently target CSC propagation, with an IC-50 as low as 500 nM. Using this approach, 2-butene-1,4-bis-TPP was the most effective compound that we identified.

RESULTS

Selective targeting of cancer cell mitochondria with TPP compounds

In order to identify new molecules that can be used to target mitochondria within CSCs, we devised a screening approach, by employing CellTiter-Glo to measure intracellular levels of ATP in adherent cancer cells (MCF-7). As ~85% of cellular ATP is normally derived from mitochondrial metabolism, ATP levels are an excellent read-out to monitor mitochondrial function. In parallel, the same 96-well plates were also stained with Hoechst 33342, to measure DNA content, to allow us to gauge cell viability.

Tri-phenyl-phosphonium (TPP) is a well-established chemical mitochondrial targeting signal. Cargo molecules covalently attached to TPP accumulate within the mitochondria of living cells. Therefore, we randomly selected 9 TPP derivatives and subjected them to screening in our assay system. The chemical structures of these TPP-derivatives are shown in Figure 1.

![Figure 1. Structures of nine TPP derivatives.](image-url)

(1) 2-butene-1,4-bis-TPP; (2) 2-chlorobenzyl-TPP; (3) 3-methylbenzyl-TPP; (4) 2,4-dichlorobenzyl-TPP; (5) 1-naphthylmethyl-TPP; (6) mito-TEMPO; (7) cyanomethyl-TPP; (8) p-xylylene-bis-TPP; (9) 4-cyanobenzyl-TPP.
Notably, five out of the nine TPP compounds were “positive hits” that significantly reduced ATP levels. These positive hits included: 2-butene-1,4-bis-TPP, 2-chlorobenzyl-TPP, 3-methylbenzyl-TPP, 2,4-dichlorobenzyl-TPP and 1-naphthylmethyl-TPP. This represents a hit rate of >50%.

However, two compounds were completely ineffective in reducing ATP levels (See Table 1). This finding is consistent with previous studies showing that the TPP moiety is not intrinsically toxic for normal cell mitochondria [21].

After initial screening, the five positive hit compounds were then subjected to further validation studies, shown in Figures 2-4, demonstrating that these TPP compounds are highly active in the range of 0.5 to 2 μM. Based on this initial analysis, 2-butene-1,4-bis-TPP appeared to be the most potent.

### Table 1. Four ineffective TPP compounds.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Hoechst staining (%)</th>
<th>ATP level (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mito-TEMPO*</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>cyanomethyl-TPP</td>
<td>97.2</td>
<td>95.1</td>
</tr>
<tr>
<td>4-cyanobenzyl-TPP</td>
<td>72.7</td>
<td>68.2</td>
</tr>
<tr>
<td>p-xylene-bis-TPP</td>
<td>69.1</td>
<td>43.9</td>
</tr>
</tbody>
</table>

*(2-(2,2,6,6-tetramethylpiperidin-1-oxy-4-ylamino)-2-oxoethyl-TPP. Cell viability and intracellular ATP levels were determined in the same treated samples. MCF-7 cell line, 50 μM treatment for 72 hours.

![Figure 2](image-url)  
**Figure 2. Effect of TPP derivatives on cell viability and intracellular ATP levels in MCF-7 human breast cancer cells: Compound 1.** Cell viability and intracellular ATP levels were determined in the same treated samples. Hoechst staining (%)(shown in black bars); ATP levels (%)(indicated in white bars. MCF-7 cells were treated for 72h. Data are represented as mean +/- SEM. Note that 2-butene-1,4-bis-TPP depletes ATP levels, relative to cell number. **p < 0.01; ***p < 0.001; indicates significance, all relative to the control.
Figure 5 highlights that these TPP compounds are relatively non-toxic in normal human fibroblasts (hTERT-BJ1), but are preferentially active in cancer cells (MCF-7). For example, in human fibroblasts, 2-butene-1,4-bis-TPP had no effect on cell viability and only mildly reduced ATP levels by 25%. In contrast, at the same concentration (1 μM) in MCF-7 cancer cells, 2-butene-1,4-bis-TPP reduced cell viability by nearly 65% and decreased ATP levels by almost 85%. Therefore, 2-butene-1,4-bis-TPP was 2.8-fold more effective at reducing cell viability in cancer cells (versus fibroblasts). Similarly, 2-butene-1,4-bis-TPP was 4.7-fold more effective at reducing ATP levels in cancer cells, relative to normal fibroblasts. Very similar results were obtained with the other TPP compounds that we evaluated.

**Identifying TPP compounds that target “malignant” mitochondria in CSCs**

To further validate that the effects we observed on reducing ATP levels were indeed due to the inhibition of mitochondrial function, we directly measured mitochondrial oxygen consumption rates (OCR) using the Seahorse XFe96 metabolic flux analyser. The results are shown in Figures 6-8. All five compounds behaved similarly, and effectively reduced basal mitochondrial respiration, with an IC-50 of approximately 1 μM.
Figure 5. Effects of TPP derivatives on cell viability and intracellular ATP levels in normal fibroblasts (hTERT-BJ1) and human breast cancer cells (MCF-7). Cell viability and intracellular ATP levels were determined in the same treated samples. Hoechst staining (%) of hTERT-BJ1 human fibroblasts (black); ATP level (%) of hTERT-BJ1 human fibroblasts (dotted); Hoechst staining (%) of MCF-7 cells (inclined lines); ATP level (%) of of MCF-7 cells (white). TPP treatments at 1 µM, 72h. Data are represented as mean +/- SEM. *p < 0.05; **p < 0.01; indicates significance, all relative to the control.

Figure 6. Impaired mitochondrial function of MCF-7 cells after treatment with various TPP derivatives: Compound 1. Oxygen consumption rate (OCR) was measured with a Seahorse XF96 Extracellular Flux Analyzer. Data are represented as mean +/- SEM. Note that 2-butene-1,4-bis-TPP effectively inhibits mitochondrial oxygen consumption. **p < 0.01; ***p < 0.001; indicates significance, all relative to the control.
We next evaluated the effects of these TPP compounds on the propagation of CSCs, using the mammosphere assay as a read-out (Figure 9). Interestingly, 2-butene-1,4-bis-TPP was the most effective, with an IC-50 < 500 nM. In contrast, for two of the other compounds tested (2-chlorobenzyl-TPP; 3-methylbenzyl-TPP) the IC-50 was between 1 to 5 μM. Finally, 1-naphthylmethyl-TPP was the least potent, with an IC-50 > 5 μM. Therefore, we conclude that 2-butene-1,4-bis-TPP is 2- to 10-fold more potent than the other TPP compounds, for inhibiting CSC propagation. This is despite the fact that they all behaved nearly identically in reducing mitochondrial respiration and ATP production. Therefore, another intrinsic property of 2-butene-1,4-bis-TPP must allow it to better target CSCs.

Finally, we used the xCELLigence system to visualize the kinetics of the effectiveness of 2-butene-1,4-bis-TPP on the proliferation of adherent MCF-7 cells, for further validation. The xCELLigence system allows the real-time, label-free, monitoring of cell health and behavior, via high frequency measurement of cell-induced electrical impedance. Figure 10 shows that the effects of 2-butene-1,4-bis-TPP are concentration-dependent and most notable after 72 hours, but are also noticeable at 48 hours. Interestingly, 2-butene-1,4-bis-TPP was cytostatic at 1 μM. However, little or no effect was observed after 24 hours of incubation, implying that the compound is not immediately cytotoxic.
Figure 9. Differential inhibition of the mammosphere-forming activity of MCF-7 breast CSCs, after treatment with various TPP derivatives. 2,4-dichlorobenzyl-TPP (black); 1-naphthymethyl-TPP (inclined lines); 3-methylbenzyl-TPP (dotted lines); 2-chlorobenzyl-TPP (white); 2-butene-1,4-bis-TPP (horizontal lines). Cells were treated for 5 days in mammosphere media. Data are represented as mean +/- SEM. Note that 2-butene-1,4-bis-TPP was the most effective compound for blocking CSC propagation, with an IC-50 less than 500 nM. *p < 0.05; **p < 0.01; indicates significance, all relative to the control.

2-Butene-1,4-bis-TPP treatment of MCF-7 cells, 72h

25,000 cells/well

Figure 10. Using the xCELLigence to assess the effects of 2-butene-1,4-bis-TPP on cell proliferation and viability/cell cycle arrest. The xCELLigence system allows the real-time, label-free, monitoring of cell health and behavior, via high frequency measurement of cell-induced electrical impedance. Note that the effects of 2-butene-1,4-bis-TPP are concentration-dependent and most notable after 72 hours, but are also noticeable at 48 hours. Little or no effect was observed after 24 hours of incubation. Interestingly, 2-butene-1,4-bis-TPP was cytostatic at 1 μM.
DISCUSSION

TPP is a mitochondrial targeting signal, which is non-toxic in normal cells [21]. We hypothesized that TPP-tagged molecules could be employed to inhibit mitochondrial function in CSCs (Figure 11). To test this hypothesis, here we used an ATP depletion assay to screen the activity of nine randomly selected TPP compounds. As a consequence, we found five TPP-related compounds that significantly suppressed ATP levels, which yields a hit-rate of more than 50%. All five positive hit compounds were subjected to functional validation with the Seahorse XFe96, to quantitate their effects on the mitochondrial oxygen consumption.

**Figure 11. Overall Work-Flow: Identifying mitochondrial inhibitors to target CSC propagation.** Here, we selected TPP-related compounds as the starting point for screening, because this ensures that all the compounds tested are targeted to mitochondria. Remarkably, we show that this strategy yields mitochondrial inhibitors of CSCs that are non-toxic in normal human fibroblasts, thereby effectively limiting drug toxicity.

**Figure 12. bis-TPP: A mitochondrial targeting signal (MTS) for eradicating cancer stem cells (CSCs).** The “dimeric” structure of bis-TPP is shown, where R represents any chemical group or moiety.
Remarkably, these TPP hit compounds were non-toxic in normal human fibroblasts and did not affect their viability or ATP production, showing striking selectivity for cancer cells. Most importantly, these TPP hit compounds successfully blocked CSC propagation, as shown by employing the 3D spheroid assay. For example, 2-butene-1,4-bis-TPP was the most potent molecule that we identified, which targeted CSC propagation with an IC-50 < 500 nM. Interestingly, 2-butene-1,4-bis-TPP contains two TPP groups. This suggests that the use of a bis-TPP moiety may function as a “dimeric” or “polymeric” signal for the more effective targeting of mitochondria in CSCs (Figure 12). However, further studies will be necessary to fully explore the potential of bis-TPP.

CONCLUSIONS

In summary, we conclude that TPP-related compounds may provide a novel chemical strategy for effectively targeting “bulk” cancer cells and CSCs, while minimizing off-target side-effects in normal cells (Figure 13).

In this context, bis-TPP may represent a more potent and selective form of TPP, especially for targeting CSCs. However, part of this potency and selectivity may also come from the reactive double bond in the central butene moiety, as p-xylylene-bis-TPP (Table 1) was ~200 times less effective than 2-butene-1,4-bis-TPP (Figure 2), in reducing overall ATP levels. See Figure 14 for a side-by-side structural comparison of these two related molecules.

SARs

<table>
<thead>
<tr>
<th>2-butene-1,4-bis-TPP</th>
<th>IC-50 (ATP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>~ 250 nM</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>p-xylylene-bis-TPP</th>
<th>~50 μM</th>
</tr>
</thead>
</table>

200 X

Figure 14. bis-TPP: Structural activity relationships (SARs). Comparison of 2-butene-1,4-bis-TPP (see Figures 1 and 2) with p-xylylene-bis-TPP (see Figure 1 and Table 1), the latter of which is approximately 200-fold less potent, in the context of ATP depletion.

MATERIALS AND METHODS

Cell culture and reagents

The human breast adenocarcinoma cell line (MCF-7) was purchased from the American Type Culture Collection (ATCC). hTERT-BJ1 cells were originally purchased from Clontech, Inc. MCF-7 and hTERT-BJ1 cells were grown in DMEM supplemented with 10% fetal bovine serum, GlutaMAX and 1% penicillin-streptomycin and incubated at 37°C in a humidified 5% CO2 incubator. The medium was changed 2-3 times/week. Nine random TPP derivatives were purchased from Santa Cruz Biotechnology, Inc., as follows: (1) 2-butene-1,4-bis-TPP; (2) 2-chlorobenzyl-TPP; (3) 3-methylbenzyl-TPP; (4) 2,4-dichlorobenzyl-TPP; (5) 1-
naphthylmethyl-TPP; (6) mito-TEMPO; (7) cyano- 
methyl-TPP; (8) p-xylylene-bis-TPP; (9) 4-cyano- 
benzyl-TPP.

**ATP-depletion assay (with CellTiter-Glo & Hoechst 33342)**

MCF-7 cells were treated with different TPP derivatives 
for 72 hours in a black 96-well plate then wells were 
washed with PBS and were stained with Hoechst 33342 
dye at a final concentration of 10 μg/ml. Fluorescence 
was read by a plate reader at 355 nm (excitation), 460 
nm (emission). After washing with PBS CellTiterGlo 
luminescent assay (Promega) was performed according 
to the manufacturer’s protocols to determine intra- 
cellular ATP levels in the Hoechst dye stained cells. 
Both the fluorescent and luminescent data were 
normalized to control levels and were shown as 
percentage for comparison.

**Measuring the mitochondrial oxygen consumption rate (OCR)**

Mitochondrial function was determined by using the XF 
Cell Mito Stress Test Kit (Seahorse Bioscience, MA, 
USA) with a Seahorse XF96 Extracellular Flux 
Analyzer (Seahorse Bioscience, MA, USA). MCF-7 
cells were seeded in a specialized 96-well tissue culture 
plate (XF96 microplate). Next day TPP derivatives were 
added and the plate was incubated for 72 hours. Before 
the experiment media was changed to XF base medium 
(including 1 mM pyruvate, 2 mM glutamine and 10 mM 
glucose) and cells were incubated at 37°C in a CO₂-free 
atmosphere for one hour before measurement. After 
detection of basal oxygen consumption rate (OCR) (an 
indicator for mitochondrial respiration) OCR responses 
were evaluated towards the application of oligomycin (1 
μM), FCCP (600 nM), and the combination of anti- 
mycin (1 μM) and rotenone (1 μM). From these 
measurements various parameters of mitochondrial 
function were determined. To determine cell viability in 
the measured wells sulphorodamine (SRB) assay was 
performed. Oxygen consumption rate (OCR) values 
were then normalized to the given SRB values.

**3D Spheroid (mammosphere) assay**

A single cell suspension of MCF-7 cells was prepared 
using enzymatic (1x Trypsin-EDTA, Sigma Aldrich, 
#T3924) and manual disaggregation (25 gauge needle). 
Cells were plated at a density of 500 cells/cm² in 
mammosphere medium (DMEM-F12 media including 
B27/20 ng/ml and EGF/PenStrep) in non-adherent 
conditions, in culture dishes coated with (2- 
hydroxyethylmethacrylate) (poly-HEMA, Sigma, 
#P3932). Different TPP derivatives were previously 
diluted in the mammosphere media before addition of 
cells. Plates were maintained in a humidified incubator 
at 37°C at an atmospheric pressure in 5% (v/v) carbon 
dioxide/air. After 5 days of culture, spheres >50 μm 
were counted using an eyepiece graticule and 
mammosphere numbers were normalized to control 
treatments (cells treated with vehicle only).

**xCELLigence RTCA System (ACEA Biosciences Inc.)**

Briefly, 25,000 MCF-7 cells were seeded in each well 
and used to assess the efficacy of 2-butene-1,4-bis-TPP, 
via RTCA (real-time cell analysis), via the measurement 
of cell-induced electrical impedance. This approach 
allows the quantification of the onset and kinetics of the 
cellular response.

**AUTHOR CONTRIBUTIONS**

Professors Lisanti and Sotgia conceived and initiated 
this project. All the experiments described in this paper 
were performed by Dr. Bela Ozsvari, who then 
generated the final figures and tables for the paper. Dr. 
Bela Ozsvari wrote the first draft of the manuscript, 
which was then further edited by Professors Lisanti and 
Sotgia. Professor Lisanti generated the schematic 
summary diagrams.

**CONFLICTS OF INTEREST**

MPL and FS hold a minority interest in Lunella, Inc.

**FUNDING**

We are grateful to the University of Manchester that 
allocated start-up funds and administered a donation, 
which provided all the necessary resources required to 
start and complete this drug discovery project (to 
M.P.L. and F.S.).

Currently, the Sotgia and Lisanti Laboratories are 
supported by private donations, the British Schools and 
Universities Foundation, the Healthy Life Foundation 
(HLF) and the Foxpoint Foundation.

**REFERENCES**

1. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, 
Sotgia F, Lisanti MP. Cancer metabolism: a 
14:11–31. https://doi.org/10.1038/nrclinonc.2016.60

2. Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, 
Sotgia F, Lisanti MP. Cancer stem cell metabolism. 


